Intravenous administration of "Muse cells" to a rabbit acute myocardial infarction model in collaboration with Professor Shinya Minatoguchi's research group at Gifu University and Professor Mari Dezawa's research group at Tohoku University will reduce the size of myocardial infarction and reduce cardiac function. It was clarified that the effect lasts for a long period of more than half a year even when it recovers and is not an autologous cell (allogeneic cell).
Acute myocardial infarction is a disease in which the blood vessels that feed the heart tissue are blocked and the heart tissue dies.On the other hand, Muse cells are pluripotent stem cells in vivo and are gradually mobilized from the bone marrow to the blood, and although there are individual differences, they circulate in the blood at a constant rate and are supplied to each organ.When cell death occurs in the tissue to which it is supplied, it differentiates according to the tissue to supplement and repair functional cells.It was discovered in 2010 by a research group at Tohoku University.
This time, autologous and allogeneic bone marrow-derived Muse cells and human bone marrow-derived Muse cells were intravenously administered to a rabbit acute myocardial infarction model.As a result, Muse cells can specifically recognize the site of injury, and spontaneously differentiate into tissues according to the tissue, become functional cells, become members of the tissue, and are integrated to repair. It was found to do (similar effect in human Muse cells).In addition, even allogeneic cells escaped immune rejection and brought about the same therapeutic effect as autologous Muse cells for a long period of more than half a year.
From this study, it was found that the repair and regeneration treatment of myocardial infarction is possible by intravenous administration of the allogeneic Muse preparation by intravenous drip.This means that if an allogeneic Muse preparation is prepared in a medical facility, it can be administered by intravenous drip, so it can be fully utilized even in an emergency, and safe and natural treatment is expected.Currently, Life Science Institute Co., Ltd. has started clinical trials for patients with myocardial infarction using allogeneic Muse cell preparations.